Foundayo
orforglipron · Eli Lilly
Form
Oral tablet
Frequency
Once daily
Available Doses
FDA Approval Date
April 1, 2026
Mechanism
Non-peptide small molecule GLP-1 receptor agonist
Manufacturer
Eli Lilly
Cost
Self-Pay
$149/mo (lowest dose) to ~$349/mo (highest dose)
With Savings Card
$25/mo for commercially insured patients
Medicare
$50/mo starting July 1, 2026
Dose-dependent pricing via LillyDirect. Most affordable FDA-approved GLP-1 at lower doses.
Side Effects
| Side Effect | Rate | Source |
|---|---|---|
| Nausea | 33.7% | ATTAIN-1, 36mg dose |
| Constipation | 25.4% | ATTAIN-1, 36mg dose |
| Vomiting | 24.0% | ATTAIN-1, 36mg dose |
| Diarrhea | 23.1% | ATTAIN-1, 36mg dose |
| Dyspepsia | 14.1% | ATTAIN-1, 36mg dose |
| Hair loss | ~4-5% | ATTAIN-1 |
| Discontinuation due to AEs | 10.3% | ATTAIN-1, 36mg dose |
Source: ATTAIN-1 Phase 3 Trial (NCT05869903), 36mg highest trial dose, 72 weeks
Weight Loss Results
ATTAIN-1 (17.2mg approved dose)
12.4% (completers) / 11.2% (ITT)
72 weeks · Multiple analyses
Highest APPROVED dose (17.2mg). Average ~27 lbs weight loss. Note: Side effect data from ATTAIN-1 comes from the 36mg trial dose (higher than approved doses). Real-world side effect rates at approved doses may be lower.
ATTAIN-1
11.2%
72 weeks · Treatment regimen (ITT)
Treatment regimen estimate — all randomized patients.
ATTAIN-1 (12mg dose)
9.3%
72 weeks · Completers analysis
Mid-range dose.
ATTAIN-1 (6mg dose)
7.8%
72 weeks · Completers analysis
Lower dose.
How It Works
Foundayo activates GLP-1 receptors in the brain and gut. This reduces appetite, increases feelings of fullness after eating, and slows the rate at which food leaves the stomach (gastric emptying). Unlike injectable GLP-1 medications that are peptide-based, orforglipron is a small molecule with high oral bioavailability, enabling it to be taken as a simple pill without fasting requirements.
Mechanism: Foundayo (orforglipron) is a non-peptide, small molecule GLP-1 receptor agonist. Unlike peptide-based GLP-1s (semaglutide, tirzepatide), orforglipron is a small molecule with high oral bioavailability (~30-40%), meaning it can be taken as a pill without food or water restrictions. It activates the GLP-1 receptor to reduce appetite, slow gastric emptying, and improve blood sugar regulation. Lilly describes it as "the ONLY GLP-1 pill that can be taken any time of day without food or water restrictions."
Who It's For
Indication
Weight management (obesity, or overweight with at least one weight-related comorbidity)
Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or high cholesterol. Ideal for patients who want oral convenience without food restrictions, are needle-averse, or are cost-sensitive.
Food & Water Restrictions
✅ No Restrictions
This medication can be taken at any time of day, with or without food and water.
Switching Guides
Comparisons
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Clinical trial data referenced comes from published studies and FDA prescribing information. Side effect rates are from specific clinical trials and may not reflect real-world experience. Always consult your healthcare provider before starting, stopping, or switching any medication.